Etid klinik pou Lupus nan Tennessee
13 etid pou Lupus ap chèche patisipan nan sit nan Tennessee.
Vil nan Tennessee
Tèks ofisyèl etid la (Anglè)
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
- West Tennessee Research Institute, Jackson
- Shelby Research LLC, Memphis
Ap rekriteFaz 3
Laj 12 a 100 · Tout sèks · Mizajou Oct 1, 2026 · NCT06133972A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
- West Tennessee Research Institute, Jackson
- Shelby Research LLC, Memphis
Ap rekriteFaz 2
Laj 18 a 74 · Tout sèks · Mizajou Oct 1, 2026 · NCT07409181A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus
- Research Site, Memphis
- Research Site, Memphis
Ap rekriteFaz 3
Laj 18 a 70 · Tout sèks · Mizajou Sep 25, 2026 · NCT07430306A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
- West Tennessee Research Institute, Jackson
Ap rekriteFaz 3
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07438496A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
- West Tennessee Research Institute - Jackson /ID# 284561, Jackson
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Sep 25, 2026 · NCT07607964A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus
- Sl0044 50001, Jackson
- Sl0044 50693, Murfreesboro
Ap rekriteFaz 3
Laj 16 ak plis · Tout sèks · Mizajou Sep 4, 2026 · NCT06617325A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants
- Murfreesboro Medical Clinic, Murfreesboro
Ap rekriteEtid obsèvasyon
Laj 16 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07175285A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE), Sjogren's Disease (SjD) and Rheumatoid Arthritis (RA)
- Private Practice - Dr. Ramesh C. Gupta /ID# 275826, Memphis
Ap rekriteFaz 1
Laj 18 a 75 · Tout sèks · Mizajou Aug 10, 2026 · NCT06977724A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
- Investigative Site, Memphis
Ap rekriteFaz 2
Laj 18 a 80 · Tout sèks · Mizajou Jul 27, 2026 · NCT07260877A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus
- Regional One Health, Memphis
Ap rekriteFaz 1
Laj 18 a 70 · Tout sèks · Mizajou Jun 5, 2026 · NCT066133602-HOBA in Systemic Lupus Erythematosus
- Vanderbilt University Medical Center, Nashville
Ap rekriteFaz 2
Laj 18 ak plis · Fanm · Mizajou May 22, 2026 · NCT07225543A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Regional One Health, Memphis
Ap rekriteFaz 1
Laj 12 a 70 · Tout sèks · Mizajou May 22, 2026 · NCT06308978Lupus Landmark Study: A Prospective Registry and Biorepository
- Vanderbilt University Medical Center, Nashville
Ap rekriteEtid obsèvasyon
Laj 18 a 110 · Tout sèks · Mizajou Apr 15, 2026 · NCT05934149Sous ClinicalTrials.gov, done yo ranmase Oct 2, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.